SI2256108T1 - Substituirani triazinski kinazni inhibitorji - Google Patents
Substituirani triazinski kinazni inhibitorjiInfo
- Publication number
- SI2256108T1 SI2256108T1 SI200332475A SI200332475A SI2256108T1 SI 2256108 T1 SI2256108 T1 SI 2256108T1 SI 200332475 A SI200332475 A SI 200332475A SI 200332475 A SI200332475 A SI 200332475A SI 2256108 T1 SI2256108 T1 SI 2256108T1
- Authority
- SI
- Slovenia
- Prior art keywords
- kinase inhibitors
- substituted triazine
- triazine kinase
- substituted
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39694802P | 2002-07-18 | 2002-07-18 | |
EP10176670.7A EP2256108B1 (en) | 2002-07-18 | 2003-07-18 | Substituted triazine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2256108T1 true SI2256108T1 (sl) | 2016-05-31 |
Family
ID=30770960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200332475A SI2256108T1 (sl) | 2002-07-18 | 2003-07-18 | Substituirani triazinski kinazni inhibitorji |
Country Status (9)
Country | Link |
---|---|
US (1) | US7205298B2 (sl) |
EP (2) | EP2256108B1 (sl) |
AU (1) | AU2003259153A1 (sl) |
CY (1) | CY1117951T1 (sl) |
DK (1) | DK2256108T3 (sl) |
ES (2) | ES2392426T3 (sl) |
HU (1) | HUE029020T2 (sl) |
SI (1) | SI2256108T1 (sl) |
WO (1) | WO2004009562A1 (sl) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0307268D0 (en) * | 2003-03-28 | 2003-05-07 | Syngenta Ltd | Organic compounds |
WO2005033095A1 (en) * | 2003-10-03 | 2005-04-14 | Dow Agrosciences Llc | Fungicidal 4-(2-aminopyridin-4-yl)-n-phenyl-1,3,5-triazin-2-amine derivatives |
JP4936897B2 (ja) | 2003-12-18 | 2012-05-23 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗増殖剤としてのピリド−およびピリミドピリミジン誘導体 |
UA84930C2 (ru) | 2004-05-14 | 2008-12-10 | Вертекс Фармасьютикалс Инкорпорейтед | Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения |
NI200700147A (es) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina inhibidores de cinasas dirigidos a multip |
NZ564179A (en) | 2005-06-30 | 2010-09-30 | Janssen Pharmaceutica Nv | Cyclic anilino - pyridinotriazines as GSK-3 inhibitors |
US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
CA2654583C (en) | 2006-07-13 | 2015-11-24 | Janssen Pharmaceutica N.V. | Mtki quinazoline derivatives |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
CA2693715C (en) | 2007-07-27 | 2015-10-27 | Janssen Pharmaceutica Nv | Pyrrolopyrimidines |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
WO2010105243A1 (en) | 2009-03-13 | 2010-09-16 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
US20130023497A1 (en) * | 2009-06-08 | 2013-01-24 | Chunlin Tao | Triazine Derivatives and their Therapeutical Applications |
US8785450B2 (en) | 2009-06-29 | 2014-07-22 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
US8415381B2 (en) * | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
EP2484683A4 (en) | 2009-09-02 | 2014-09-03 | Lg Chemical Ltd | ORGANOTINE COMPOUND, PROCESS FOR THE PREPARATION THEREOF AND METHOD FOR THE PRODUCTION OF POLYMILIC ACID THEREWITH |
EP3561077B1 (en) | 2009-10-21 | 2022-12-21 | Les Laboratoires Servier | Methods for cell-proliferation-related disorders |
RS54544B1 (en) | 2010-09-13 | 2016-06-30 | Novartis Ag | TRIAZINE-OXADIAZOLES |
EA201390717A1 (ru) * | 2010-11-17 | 2013-10-30 | Новартис Аг | 3-(аминоарил)пиридиновые соединения |
CN103339110A (zh) * | 2011-01-28 | 2013-10-02 | 诺瓦提斯公司 | 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途 |
WO2012117048A1 (en) * | 2011-03-02 | 2012-09-07 | Lead Discovery Center Gmbh | Pharmaceutically active disubstituted triazine derivatives |
US9242937B2 (en) | 2011-03-02 | 2016-01-26 | Bayer Intellectual Property Gmbh | Pharmaceutically active disubstituted pyridine derivatives |
MX2013012233A (es) | 2011-04-19 | 2014-01-23 | Bayer Pharma AG | 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas. |
PL3406251T3 (pl) | 2011-05-03 | 2024-04-29 | Agios Pharmaceuticals, Inc. | Aktywatory kinazy pirogronianowej do stosowania w terapii |
TW201636330A (zh) | 2011-05-24 | 2016-10-16 | 拜耳知識產權公司 | 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺 |
AU2012262489A1 (en) | 2011-05-27 | 2013-04-04 | Icahn School Of Medicine At Mount Sinai | Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones, derivatives thereof, and therapeutic uses thereof |
CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
WO2013033657A2 (en) | 2011-09-02 | 2013-03-07 | The Trustees Of Columbia University In The City Of New York | CaMKII, IP3R, CALCINEURIN, P38 AND MK2/3 INHIBITORS TO TREAT METABOLIC DISTURBANCES OF OBESITY |
EP2755948B1 (en) | 2011-09-16 | 2016-05-25 | Bayer Intellectual Property GmbH | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group |
CA2848616A1 (en) | 2011-09-16 | 2013-03-21 | Bayer Intellectual Property Gmbh | Disubstituted 5-fluoro-pyrimidines |
EP2785721A1 (en) | 2011-11-30 | 2014-10-08 | Actelion Pharmaceuticals Ltd. | 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics |
SI2800743T1 (sl) | 2012-01-06 | 2018-08-31 | Agios Pharmaceuticals, Inc. | Terapevtsko aktivne spojine in načini njihove uporabe |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
WO2014062511A1 (en) | 2012-10-15 | 2014-04-24 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
CA2888381A1 (en) | 2012-10-18 | 2014-04-24 | Bayer Pharma Aktiengesellschaft | 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group |
CN104854091B (zh) | 2012-10-18 | 2018-04-03 | 拜耳药业股份公司 | 含砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物 |
TW201418243A (zh) | 2012-11-15 | 2014-05-16 | Bayer Pharma AG | 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物 |
TW201429972A (zh) | 2013-01-09 | 2014-08-01 | Actelion Pharmaceuticals Ltd | 抗菌噁唑酮衍生物 |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
EP3019480B1 (en) | 2013-07-11 | 2020-05-06 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
MY185687A (en) * | 2013-07-11 | 2021-05-30 | Agios Pharmaceuticals Inc | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
EA030428B1 (ru) | 2013-08-02 | 2018-08-31 | Аджиос Фармасьютикалз, Инк. | Терапевтически активные соединения и способы их применения |
US20160221991A1 (en) * | 2013-09-20 | 2016-08-04 | Carna Biosciences, Inc. | Novel triazine derivative |
KR102400737B1 (ko) | 2014-03-14 | 2022-05-20 | 아지오스 파마슈티컬스 아이엔씨. | 치료적으로 활성인 화합물의 약제학적 조성물 |
CN107207475A (zh) | 2014-10-16 | 2017-09-26 | 拜耳医药股份有限公司 | 含有砜基团的氟化苯并呋喃基‑嘧啶衍生物 |
CN107427520A (zh) | 2015-03-24 | 2017-12-01 | 拜耳医药股份有限公司 | 4‑(4‑氟‑2‑甲氧基苯基)‑n‑{3‑[(s‑甲基磺酰亚氨基)甲基]苯基}‑1,3,5‑三嗪‑2‑胺用于治疗淋巴瘤的用途 |
CA2980493A1 (en) | 2015-03-24 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating multiple myeloma |
WO2016150902A1 (en) | 2015-03-24 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers |
WO2016201227A1 (en) | 2015-06-11 | 2016-12-15 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
AU2016303614A1 (en) | 2015-08-05 | 2018-02-15 | Agios Pharmaceuticals, Inc. | Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines |
CN108290903B (zh) | 2015-09-29 | 2021-09-03 | 拜耳医药股份有限公司 | 新的大环磺酰二亚胺化合物 |
EP3359544B1 (en) | 2015-10-08 | 2020-08-12 | Bayer Pharma Aktiengesellschaft | Novel modified macrocyclic compounds |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
MD3362066T2 (ro) | 2015-10-15 | 2022-08-31 | Les Laboratoires Servier Sas | Terapie combinată pentru tratamentul tumorilor maligne |
EP4403173A3 (en) | 2015-10-15 | 2024-10-09 | Les Laboratoires Servier | Combination therapy for treating malignancies |
EP3601253B1 (en) | 2017-03-28 | 2021-09-15 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
WO2018177889A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
BR112020016389A2 (pt) | 2018-02-13 | 2020-12-15 | Bayer Aktiengesellschaft | Uso de 5-fluor-4-(4-fluor-2-metoxifenil)-n-{4-[(s-metilsulfonimidoil)metil]piridin-2-il}piridin-2-amina para tratamento de linfoma difuso de células b grandes |
US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
CN109503473B (zh) * | 2019-01-07 | 2020-07-07 | 上海慧川生物医药科技有限公司 | 2-甲氧基-3-氨基-5-吡啶硼酸频哪醇酯及其中间体的合成方法 |
CN110357863B (zh) * | 2019-08-27 | 2023-04-14 | 药雅科技(上海)有限公司 | 一种三嗪双芳香环衍生物表皮生长因子抑制剂及其制备方法与用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69332948T2 (de) | 1992-03-05 | 2003-11-27 | Board Of Regents, The University Of Texas System | Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren |
US5474765A (en) | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
US5902795A (en) | 1992-06-16 | 1999-05-11 | Trustees Of Tufts College | Oligosaccharides reactive with hyaluronan-binding protein and their methods of use |
CA2216943C (en) | 1995-04-19 | 2003-06-17 | Schneider (Usa) Inc. | Drug release coated stent |
US6342221B1 (en) | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody conjugate compositions for selectively inhibiting VEGF |
AU770600B2 (en) | 1999-10-07 | 2004-02-26 | Amgen, Inc. | Triazine kinase inhibitors |
US6776796B2 (en) | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
JP3499808B2 (ja) | 2000-06-29 | 2004-02-23 | 本田技研工業株式会社 | 電子文書分類システム |
-
2003
- 2003-07-18 SI SI200332475A patent/SI2256108T1/sl unknown
- 2003-07-18 HU HUE10176670A patent/HUE029020T2/en unknown
- 2003-07-18 US US10/622,721 patent/US7205298B2/en not_active Expired - Lifetime
- 2003-07-18 WO PCT/US2003/022390 patent/WO2004009562A1/en not_active Application Discontinuation
- 2003-07-18 EP EP10176670.7A patent/EP2256108B1/en not_active Expired - Lifetime
- 2003-07-18 ES ES03765676T patent/ES2392426T3/es not_active Expired - Lifetime
- 2003-07-18 ES ES10176670.7T patent/ES2575522T3/es not_active Expired - Lifetime
- 2003-07-18 DK DK10176670.7T patent/DK2256108T3/en active
- 2003-07-18 EP EP03765676A patent/EP1546121B1/en not_active Expired - Lifetime
- 2003-07-18 AU AU2003259153A patent/AU2003259153A1/en not_active Abandoned
-
2016
- 2016-06-13 CY CY20161100515T patent/CY1117951T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ES2392426T3 (es) | 2012-12-10 |
US7205298B2 (en) | 2007-04-17 |
HUE029020T2 (en) | 2017-02-28 |
ES2575522T3 (es) | 2016-06-29 |
US20040082581A1 (en) | 2004-04-29 |
EP1546121B1 (en) | 2012-08-29 |
EP2256108A1 (en) | 2010-12-01 |
CY1117951T1 (el) | 2017-05-17 |
EP1546121A1 (en) | 2005-06-29 |
AU2003259153A1 (en) | 2004-02-09 |
DK2256108T3 (en) | 2016-04-11 |
EP2256108B1 (en) | 2016-03-23 |
EP1546121A4 (en) | 2007-08-15 |
WO2004009562A1 (en) | 2004-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2256108T1 (sl) | Substituirani triazinski kinazni inhibitorji | |
PL373649A1 (en) | Kinase inhibitors | |
SI1569907T1 (sl) | Na nikotinamidu osnovani kinazni inhibitorji | |
AU2003271566A8 (en) | Pyrrolopyrazines as kinase inhibitors | |
IL165515A0 (en) | Bisindolyl-maleimid derivatives as kinase inhibitors | |
AU2003299651A8 (en) | Tyrosine kinase inhibitors | |
EP1558609A4 (en) | KINASE INHIBITORS | |
EP1543009A4 (en) | Pyrrolotriazine KINASE INHIBITORS | |
EP1539763A4 (en) | Azaindole KINASE INHIBITORS | |
IL173381A0 (en) | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors | |
AP2048A (en) | Diazepinoindole derivatives as kinase inhibitors | |
AU2003249442A1 (en) | Kinase inhibitors | |
AU2003298942A8 (en) | Tyrosine kinase inhibitors | |
IL172132A0 (en) | Thienopyridone derivatives as kinase inhibitors | |
AP2006003620A0 (en) | Imidazopyrazine tyroshine kinase inhibitors | |
AU2003282891A8 (en) | Novel tyrosine kinases inhibitors | |
EP1497019A4 (en) | USE AS KINASEINHIBITORS USEFUL PYRROLO-TRIAZIN-ANILINE COMPOUNDS | |
IL173200A0 (en) | Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors | |
EP1534268A4 (en) | TYROSINE KINASE INHIBITORS | |
EP1581539A4 (en) | NEW TYROSINE KINASE HEMMER | |
HK1071758A1 (en) | Pyrazolopyridines as cyclin dependent kinase inhibitors | |
AU2003275282A8 (en) | Novel tyrosine kinase inhibitors | |
AU2003237446A1 (en) | Pyrazole-derivatives as p38 kinase inhibitors | |
AU2003254051A8 (en) | Pyrazolopyrimidines as kinase inhibitors | |
PL378116A1 (pl) | Heterocykliczne inhibitory kinazy |